Trials / Completed
CompletedNCT06264440
A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants
A Phase 1, Open-Label, Crossover Study to Assess the Potential for Gastric pH-Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of the study is to evaluate the effects of a proton pump inhibitor (PPI) \[rabeprazole\] on BIIB122 pharmacokinetics (PK) after a single dose in healthy participants. The secondary objective of the study is to evaluate the safety and tolerability of BIIB122, with and without a PPI (rabeprazole), after a single dose in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIIB122 | Administered as specified in the treatment arm. |
| DRUG | Rabeprazole | Administered as specified in the treatment arm. |
Timeline
- Start date
- 2024-02-12
- Primary completion
- 2024-06-18
- Completion
- 2024-06-18
- First posted
- 2024-02-20
- Last updated
- 2024-07-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06264440. Inclusion in this directory is not an endorsement.